Company Overview of Vaxin Inc.
Vaxin Inc. develops vaccines and other biological products to control infectious diseases. It provides vaccines to protect people against influenza and anthrax infection using proprietary technologies for intranasal delivery. The company provides AdVAV anthrax vaccine; NasoVAX pre-pandemic influenza (bird-flu) vaccine, a non-replicating adenovirus encoding the hemagglutinin (HA) protein from the influenza virus; and NasoVAX seasonal influenza vaccine. It also develops vaccines for animal health, including vaccines to protect poultry and swine, and a vaccine to sterilize cats and dogs. Vaxin Inc. was formerly known as ImmuneFocus Corporation. The company was founded in 1997 and is based in Ga...
19 Firstfield Road
Gaithersburg, MD 20878
Founded in 1997
Key Executives for Vaxin Inc.
Chief Executive Officer, President and Director
Corporate Counsel and Secretary
Compensation as of Fiscal Year 2014.
Vaxin Inc. Key Developments
Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM
Mar 17 15
Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: William Enright, Chief Executive Officer, President and Director.
Vaxin Inc. and Immune Targeting Systems (ITS) Limited Announce Board Changes
Feb 17 15
Vaxin Inc. announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Dr. David Drutz, (Executive Chairman and Chief Medical Officer, DARA BioSciences) will remain Chairman of the combined company. Other board members include Brigadier General (ret.) Klaus Schafer, MD, MPH, Philip Hodges (Redmont Capital), Florent Gros (Novartis Venture Fund), Philippe Pouletty, MD (Truffle Capital), Marten Steen, MD, PhD (HealthCap) and Bill Enright (Vaxin CEO).
Vaxin Inc. Secures $16 Million in New Financing
Feb 17 15
Vaxin announced $16 million in new committed financing, with investors in both companies planning to participate, including Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. To date, the companies have collectively raised more than $100 million in dilutive and non-dilutive funding.
Similar Private Companies By Industry
Recent Private Companies Transactions